ReviewAmerican journal of Alzheimer's disease and other dementias
Donepezil in severe Alzheimer's disease.
Review in American journal of Alzheimer's disease and other dementias. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.The Cochrane database of systematic reviews · 2021Pooled it
- Current and emerging drug treatment options for Alzheimer's disease: a systematic review.Drugs · 2011Pooled it
- Neuroprotective effects of cordycepin inhibit glutamate-induced apoptosis in hippocampal neurons.Cell stress & chaperones · 2024Article
- Peripheral Nerve Impairment in a Mouse Model of Alzheimer's Disease.Brain sciences · 2021Article
- Protective effect of a calcium channel blocker "diltiazem" on aluminum chloride-induced dementia in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2015Article
- Dual roles for autophagy: degradation and secretion of Alzheimer's disease Aβ peptide.BioEssays : news and reviews in molecular, cellular and developmental biology · 2014Review
- Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease.Psychopharmacology · 2013Article
- Treatment of Alzheimer's Disease: Current Management and Experimental Therapeutics.Current translational geriatrics and experimental gerontology reports · 2013Article
- Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.Alzheimer's research & therapy · 2013Article
- Natural products as promising drug candidates for the treatment of Alzheimer's disease: molecular mechanism aspect.Current neuropharmacology · 2013Article
- Current neuroimaging techniques in Alzheimer's disease and applications in animal models.American journal of nuclear medicine and molecular imaging · 2012Article
- Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia.Journal of the American Geriatrics Society · 2011Article
- Rehabilitating a brain with Alzheimer's: a proposal.Clinical interventions in aging · 2011Review
- Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying?Drugs & aging · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the severe stages of Alzheimer's disease, functional autonomy is lost, psychiatric and behavioral symptoms become increasingly troublesome, and cognitive deficits increase until most patients require complete care, usually in specialized nursing homes. Consequently,some health care professionals question the benefits of pharmacologic intervention during these later stages. Since primary care physicians are often first to see these patients, they have key roles in recognizing the benefits of treatment and initiating appropriate management and referral. Three prospective randomized clinical trials of donepezil in severe Alzheimer's disease have been conducted; these show donepezil treatment is associated with functional and cognitive benefits, although behavioral benefits were not consistently observed. Donepezil was well tolerated; side effects were transient, mild to moderately severe, and cholinergic in nature. Donepezil has strong data throughout the Alzheimer's disease spectrum and, therefore, represents a first-line monotherapy that can provide benefits to patients in all stages of Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.